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of 0.5 (95%CI: 0.3-0.8) for DRSP/estradiol vs. other occHRT. ConClusions: Results 
indicate a good safety profile with respect to cardiovascular risk for DRSP/estra-
diol. Serious cardiovascular events occur less frequently in DRSP/estradiol users 
compared to users of other continuous-combined HRT. This specificAS approach 
proved to be a successful approach with high long term follow-up success and 
high validity of safety results.
IndIvIdual’s HealtH – Cost studies
PIH7
Budget ImPaCt of HPv16/18 genotyPIng tests for tHe management of 
non-ConCordant CotestIng CervICal CanCer sCreenIng results: a 
unIted states Payer PersPeCtIve
Huang J.1, Hertz D.2, Conner A.2, Garfield S.2
1Roche Molecular Diagnostics, Pleasanton, CA, USA, 2GfK Bridgehead, Wayland, MA, USA
objeCtives: To assess the impact of managing women with high-risk HPV positive 
and Pap negative results (hrHPV+/Pap-) attending cervical cancer (CxCa) screening 
with a Pap and HPV test (co-testing). The strategies tested reflect different options 
available if a hrHPV test versus a hrHPV including 16/18 genotyping (3-in-1 test) 
is used upon initial screen. Methods: A budget-impact model was developed, 
from a US payer perspective. Data from the ATHENA (Addressing THE Need for 
Advanced HPV Diagnostics) trial and published literature were used to populate 
the model. The scenarios tested include repeat co-testing in 12 months, reflex 
genotyping HPV16/18, or routine co-testing with genotyping results already avail-
able from a 3-in-1 test for triage to colposcopy. The model examined the annual 
cost of testing and treatment for cervical intraepithelial neoplasia grade 2 or worse 
(≥ CIN2) and the cost of patients loss-to-follow-up. For a hypothetical population 
of women between ages 30 to 69, it assumes 48.5% were co-tested within the CxCa 
screening program every 3 years. Of those, 6.7% of women receive hrHPV+/Pap- 
results. Test performance was modeled as equivalent for both genotyping sce-
narios. Results: In the hrHPV+/Pap- population, the cost of ≥ CIN2 cases detected 
and treated for each testing strategy and the rate of progression to invasive CxCa 
per 10,000 hrHPV+/Pap- results was $10,530/9.2 (repeat co-testing at 12 months), 
$8,500/2.6 (reflex HPV16/18) and $7,278/2.6 (routine co-testing with 3-in-1 test). 
Using HPV16/18 genotyping to manage discordant co-testing results increased 
≥ CIN2 cases detected and prevented disease progression. Compared to other HPV 
tests that require reflex genotyping, screening with a 3-in-1 test reduced the cost 
of follow-up by 17% annually. ConClusions: Genotyping for HPV 16/18 improved 
the detection of ≥ CIN2 cases over repeat co-testing in 12 months; moreover, com-
pared to other HPV testing strategies, the 3-in-1 test reduced costs and may be a 
prudent screening alternative.
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objeCtives: Abdominal adhesions are common after gynecologic surgeries, 
often resulting in complications such as bowel obstruction and chronic pain, 
which may lead to increased length of stay and more frequent readmissions. 
GYNECARE INTERCEED® Absorbable Adhesion Barrier is associated with fewer 
adhesion-related outcomes compared to surgeries without an adhesion-barrier. 
This analysis assesses the budget impact of GYNECARE INTERCEED® for reduc-
ing the incidence of postoperative adhesions in open surgical gynecologic pro-
cedures. Methods: A model was constructed to evaluate the budget impact to 
hospitals of adopting GYNECARE INTERCEED® for women undergoing open surgical 
gynecologic procedures. C-section surgery, hysterectomy, myomectomy, ovarian 
surgery, tubal surgery, and endometriosis surgery were modeled with and without 
the use of GYNECARE INTERCEED®. Incremental GYNECARE INTERCEED® material 
costs, medical costs arising from complications, and adhesion-related readmis-
sions were considered. GYNECARE INTERCEED® use was assumed in 50% of all 
procedures. Budget impact was reported over a 3-year period from a US hospital 
perspective (US$2013). Results: Assuming 100 gynecologic surgeries of each type 
and an average of one GYNECARE INTERCEED® sheet per surgery, a net savings 
of $439,975 with GYNECARE INTERCEED® over 3 years is estimated. GYNECARE 
INTERCEED® use resulted in 80 fewer patient cases developing adhesions. Although 
the use of GYNECARE INTERCEED® added $91,500 in material costs, this was com-
pletely offset by the reduction in complication costs ($230,766 savings) and fewer 
adhesion-related readmissions ($300,709 savings). By preventing adhesion-related 
complications, GYNECARE INTERCEED® prevented over 206 additional hospital days 
for patients. ConClusions: This analysis represents the first economic assess-
ment of GYNECARE INTERCEED® use in open gynecologic surgeries that incorpo-
rates the cost of the adhesion barrier, complications, and readmissions. Adoption 
of GYNECARE INTERCEED® absorbable adhesion barrier for appropriate gynecologic 
surgeries would likely result in significant savings for hospitals which would largely 
be driven by clinical patient benefits in terms of fewer complications and adhesion-
related readmissions.
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objeCtives: Evaluate the budget impact to the public health care system in 
Brazil after introducing dienogest (2 mg) as a treatment option in detriment of 
GnRH analogues (GnRHa) for patients with endometriosis-associated pelvic pain 
(EAPP). Methods: The analysis was conducted from the public perspective over 
a five-year time horizon. The budget impact model (BIM) specifically considered 
comparison to UAE (pregnancies: 3.44, 95%CI 1.18- 10.03; live-births: 3.02, 95%CI 
1.00- 9.09). ConClusions: LUAO is less effective than UAE and MYO in the treat-
ment of symptomatic fibroids for women who want to preserve their uterus. The 
choice between UAE and MYO should be based on individuals’ short and long-
term expectations.
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objeCtives: BCG vaccination policy is greatly debated. An important issue for coun-
tries using the vaccine is to try and estimate any influence it has on the tuberculosis 
(TB) incidence in their population. The aim of this study is to estimate the effective-
ness of the BCG vaccine in infants in Ireland. Methods: We searched PubMed and 
Embase for studies assessing a relative reduction in TB events after vaccination 
in infants. Studies meeting relevant inclusion and exclusion criteria were sought. 
Observational data from Ireland was combined with raw data from studies identified 
in the literature in a random-effects meta-analysis model to estimate the relative 
risk (RR) of vaccine efficacy against pulmonary TB, extra-pulmonary TB (EPTB), TB 
meningitis and TB deaths. Results: Two meta-analyses were found. The first meta-
analysis reviewed identified 5 randomised control trials and 11 case control studies 
against pulmonary TB (Trials 0.26 95% CI 0.17, 0.38; Cases 0.48 95% CI 0.37, 0.62) 
and TB deaths (Trials 0.35 95% CI 0.14, 0.88). The second meta-analysis identified a 
further 7 case-control studies and evaluated BCG efficacy against EPTB (0.23 95%CI 
0.13, 0.42] and TB meningitis (0.27 95%CI 0.21, 0.33). Estimates from observational 
data from Ireland for pulmonary TB were (0.14, 95%CI 0.09, 0.20), EPTB (0.11, 95%CI 
0.05, 0.21), TB meningitis (0.17, 95%CI 0.04, 0.75) and TB deaths (0.13, 95%CI 0.00, 6.37). 
Pooled RR estimates from Irish data and international estimates show a significant 
reduction in TB cases: Pulmonary TB: 0.26 (95% CI: 0.13, 0.54), EPTB: 0.16 (95%CI: 
0.08, 0.34), TB meningitis: 0.27 (95%CI: 0.21, 0.34) and TB deaths: 0.33 (95%CI: 0.14, 
0.81). ConClusions: This meta-analysis of local observational data with interna-
tional trial data indicates that vaccination of infants with the BCG vaccine reduces 
the risk of pulmonary TB, EPTB, TB meningitis and TB deaths.
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objeCtives: The use of antipsychotics for people with dementia is regarded as 
problematic, causing cerebrovascular side effects and increasing mortality. In 
some countries, health-policy makers have already addressed a need for action 
to reduce the prescription of antipsychotics in dementia. The main goal of the 
analysis is to determine the extent of co-medication of antipsychotics for patients 
with medically-treated dementia in Austria, stratified by age and sex. Methods: 
Provided in a pseudonymised manner, the data comprise all filled prescriptions of 
cholinesterase inhibitors and memantine in the years 2011 and 2012 at the expense 
of the 13 major Austrian health insurance funds, covering more than 97% of the 
Austrian population. Additionally, antipsychotic medication of the involved patient 
pseudonyms is included, as well as age, sex and – where occurred – date of death. 
For the analysis, the overlapping time frame is relevant, i.e. when both substance 
groups were consumed. Descriptive statistics are used to capture the extent and 
variability of a co-medication of these two substance groups. Results: Starting 
with 72,549 patients included in the data (66% female), 31,605 (43.6%) were concur-
rently being prescribed antipsychotics to their anti-dementia drugs. The median 
for the overlapping time frame is 294 days, for anti-dementia prescriptions it is 
eleven and for antipsychotics it is seven. Age is a factor for increasing antipsy-
chotic medication. Considering demography, there are no remarkable differences 
between men and women. ConClusions: Our data demonstrate that the use of 
antipsychotics in dementia is notably common in Austria, with a high prevalence 
as well as a tendency to long-term use. The results reflect the prescription reality 
and can be used as a solid basis for discussions, possible actions and evaluations 
about antipsychotics in dementia in the Austrian health system.
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objeCtives: The novel progestin drospirenone (DRSP) has antimineralocorticoid 
properties with potentially beneficial as well as unfavorable effects on cardiovas-
cular outcomes compared to other progestins. A patient based AS study was set 
up to compare incidence rates of serious adverse events – in particular cardiovas-
cular outcomes - in users of oral continuous combined preparations. Methods: 
Prospective, controlled cohort study (2002-2011) with three arms: women using 
1) DRSP/estradiol; 2) other oral continuous-combined HRT (occHRT); and 3) all 
other oral HRTs. The study population included women aged 40 or older in seven 
European countries starting or switching to an oral HRT at time of inclusion in the 
study. Outcomes were collected from the patients and validated by the treating 
physicians. A multifaceted 4-level follow-up procedure was to ensure low loss to 
follow-up rates. The analysis is based on Cox regression models comparing the 
cohorts. Results: A total of 30,597 users of oral HRT preparations – reflecting 
more than 101,000 WY of observation – were recruited by 1,052 centers. Incidence 
rates of DRSP/estradiol and low-dose occHRT for venous thromboembolic events 
were 17.5 (95% CI: 11.2-26.0) and 18.2 (95% CI: 11.9-26.6) per 10,000 WY, respectively. 
The respective incidence rates for arterial thromboembolism were 10.9 (95% CI: 
6.1-18.0) and 29.8 (95% CI: 24.1-36.4 ) per 10,000 WY with a hazard ratio adjusted 
for age, BMI, hypertension, region, family history of fatal ATE, diabetes, user status 
